Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Atea Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing orally administered antiviral therapies for serious viral diseases. Its lead product candidate is a fixed-dose combination of bemnifosbuvir and ruzasvir for treating chronic hepatitis C virus (HCV) infection. The company targets global HCV patients with a pan-genotypic, protease inhibitor-free regimen designed for improved efficacy, tolerability, and convenience compared to current standards of care.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Atea Pharmaceuticals, Inc.

1
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports $45.4 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports Year-End Financial Results with Decreased Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports $42M Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports $37.2 Million Net Loss in Q2 2025, Decreasing from Previous Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports $34.3 Million Net Loss in Q1 2025, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports $168.4 Million Net Loss for 2024, Plans Phase 3 Trials for HCV Treatment

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals Reports Mixed Financial Results, Narrowing Net Loss and Declining Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments